NYSE: IBO · Life Sciences · 5 alerts · CIK 1834105
Share price
$4.91Close, Nov 16
Market cap
$42.4M
Shares outstanding
8.64MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Impact Biomedical Inc. filings on SEC EDGAR ↗
Impact BioMedical reported a net loss of $3.63 million for the nine months ended September 30, 2026, a significant improvement from the $17.11 million loss in the prior year period which was driven by a $13.21 million change in fair value of a related party note. The company maintains a minimal revenue base of $31,000 and continues to focus on developing its proprietary healthcare technologies like Linebacker™.
Impact Biomedical Inc. announced that the SEC has declared effective the Form F-4 registration statement for its proposed merger with Zoar Limited. A special meeting of stockholders to approve the business combination is scheduled for November 13, 2026, with the combined company expected to trade under the ticker symbol 'ZOAR'.
Impact BioMedical Inc. implemented a 1-for-12.62 reverse stock split of its common stock effective September 23, 2026. The split reduced the number of outstanding shares from approximately 107.8 million to 8.6 million to adjust the company's capital structure. The stock began trading on a split-adjusted basis on the NYSE American under the existing ticker symbol 'IBO'.
Impact Biomedical Inc. announced the filing of a Form F-4 registration statement by Zoar Limited in connection with their previously announced business combination. The filing represents a major milestone toward closing the merger, which will result in a combined pharmaceutical company focused on active pharmaceutical ingredients and special therapeutic treatments. The transaction remains subject to SEC effectiveness, stockholder approval, and NYSE American listing approval.
Impact Biomedical Inc. announced a 1-for-12.62 reverse stock split effective September 23, 2026, reducing outstanding shares from approximately 107.8 million to 8.5 million. The split is intended to regain compliance with NYSE American listing requirements and facilitate its proposed merger with Zoar Limited. Following the split and merger closing, Impact stockholders are expected to receive one share of Zoar Limited for every one share of Impact common stock held.